Mod­er­na's new Covid-19 vac­cine analy­sis 'giv­ing weight' to an­nu­al boost­ing in­ter­val, com­pa­ny says

Mod­er­na’s Covid-19 vac­cine study sug­gests a longer in­ter­val be­tween boost­ers is more ben­e­fi­cial in the gen­er­al adult pop­u­la­tion, sup­port­ing the FDA’s pre­vi­ous pro­pos­al for an an­nu­al boost­ing strat­e­gy.

Mod­er­na an­a­lyzed the ef­fi­ca­cy of a sin­gle boost­er of its orig­i­nal vac­cine in around 17,000 par­tic­i­pants en­rolled in its Phase III COVE study from Sept. 2021 to May 2022, the com­pa­ny an­nounced Wednes­day at the ID­Week con­fer­ence in Boston. The tri­al in­clud­ed par­tic­i­pants who re­ceived a boost­er shot rough­ly 12 to 13 months af­ter their pri­ma­ry se­ries, as well as those who ini­tial­ly re­ceived a place­bo be­fore mov­ing to the open-la­bel phase and were boost­ed af­ter rough­ly eight months, ac­cord­ing to Fran Prid­dy, ex­ec­u­tive di­rec­tor of clin­i­cal de­vel­op­ment in Mod­er­na’s Covid vac­cines unit.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.